Technology
Health
Biotechnology

Stemline

$12.21
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.16 (-1.29%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell Stemline and other stocks, options, ETFs, and crypto commission-free!

About

Stemline Therapeutics, Inc. Common Stock, also called Stemline, is a clinical stage biopharmaceutical company, which engages in the discovery, acquisition, development, and commercialization of novel therapeutics for oncology indications of unmet medical need. Read More Its clinical stage product candidates include SL-401, SL-801, and SL-701. The SL-401, is a targeted therapy directed to the interleukin-3 receptor (CD123) present on a malignancies. The SL-801, is a novel oral small molecule reversible inhibitor of XPO1, that has demonstrated in vivo and in vitro preclinical activity in a solid and hematologic malignancies. The SL-701, is an immunotherapy designed to activate the immune system to attack tumors. The company was founded by Ivan Bergstein on August 8, 2003 and is headquartered in New York, NY.

Employees
92
Headquarters
New York, New York
Founded
2003
Market Cap
395.14M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
370.72K
High Today
$12.43
Low Today
$12.07
Open Price
$12.37
Volume
294.99K
52 Week High
$20.55
52 Week Low
$7.82

Collections

Technology
Health
Biotechnology
Medical
Therapy
Biopharmaceutical
Pharmaceutical
2013 IPO

News

Simply Wall StMar 5

If You Had Bought Stemline Therapeutics Shares Three Years Ago You’d Have Made 93%

One simple way to benefit from the stock market is to buy an index fund. But if you pick the right individual stocks, you could make more than that. For example, Stemline Therapeutics, Inc. (NASDAQ:STML) shareholders have seen the share price rise 93% over three years, well in excess of the market return (41%, not including dividends). View our latest analysis for Stemline Therapeutics We don’t think Stemline Therapeutics’s revenue of US$500,000 is enough to establish significant demand. So it seems share...

441
MarketBeatFeb 23

Stock Price, News, & Analysis for Stemline Therapeutics

Stemline Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of proprietary oncology therapeutics in the United States and internationally. The company develops SL-401, a targeted therapy directed to the interleukin-3 receptor (IL-3R), which has completed Phase II clinical trial for patients with blastic plasmacytoid dendritic cell neoplasm; is in Phase I/II clinical trials for patients with myeloproliferative neoplasms, c...

258

Earnings

-$0.93
-$0.79
-$0.64
-$0.50
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
-$0.74 per share
Actual
-$0.92 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.